Risa Tanabe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Risa Tanabe has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Yoshinobu Hamada
Department of Obstetrics and Gynecology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan
3 shared publications - Akiyoshi Nakayama
Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan
2 shared publications - Hiroaki Soyama
Department of Obstetrics and Gynecology, Takanohara Central Hospital
2 shared publications - Hirofumi Nakaoka
Department of Biomedical Data Science, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
2 shared publications - Hiroshi Nakashima
Department of Preventive Medicine and Public Health, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan
2 shared publications - Hirotaka Matsuo
Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan.
2 shared publications
Latest Publications
- Open Access
- 18 June 2026
- Published by Springer Nature in Human Cell
- Vol. 39 (7)
Effects of ABCG2 dysfunction on hyperuricemia progression in premenopausal and postmenopausal women
Serum uric acid (SUA) levels are influenced by environmental and genetic factors, such as sex and ABCG2 variants. Their poorlyunderstood links to menstrual status prompted us to conduct this study to evaluate the effects of menstrual status-related ABCG2 function, detectable from the presence of its dysfunctional variants, on SUA levels. Recruited for the present study were 9244 Japanese individuals, comprising 4466 women and 4778 men. We evaluated the effect size on SUA and population attributable fractions (PAFs) for hyperuricemia progression based on factors, including ABCG2 function, BMI, alcohol consumption, age, and menstrual status (in women). The results, from the viewpoint of SUA increase, showed a 25% ABCG2 dysfunction to be equivalent to the effects of a 1.67 kg/m 2 increase in BMI, alcohol consumption of 154.2 g/week, an 18.6-year increase in age, and, in women, 42.7% due to menopause. In the tested female sample, the PAF for hyperuricemia due to ABCG2 dysfunction (32.8%) exceeded those for overweight/obesity (19.5%) and aging (28.7%). Menopausal status exhibited the highest PAF at 63.0%. In premenopausal individuals, the PAF for ABCG2 dysfunction was 45.8%, much higher than that after menopause (29.6%). Although premenopausal women generally had a lower prevalence of hyperuricemia than postmenopausal individuals, those with dysfunctional variants of ABCG2 tended to show a higher SUA increase and PAFs in premenopausal than in postmenopausal women. These results indicate that genetic testing might be helpful in preventing and treating hyperuricemia, particularly for those with higher SUA before menopause, in both individuals and in populations as a whole.
- 18 June 2026
- Published by Springer Nature in Human Cell
- Vol. 39 (7)
Open AccessEffects of ABCG2 dysfunction on hyperuricemia progression in premenopausal and postmenopausal women
Serum uric acid (SUA) levels are influenced by environmental and genetic factors, such as sex and ABCG2 variants. Their poorlyunderstood links to menstrual status prompted us to conduct this study to evaluate the effects of menstrual status-related ABCG2 function, detectable from the presence of its dysfunctional variants, on SUA levels. Recruited for the present study were 9244 Japanese individuals, comprising 4466 women and 4778 men. We evaluated the effect size on SUA and population attributable fractions (PAFs) for hyperuricemia progression based on factors, including ABCG2 function, BMI, alcohol consumption, age, and menstrual status (in women). The results, from the viewpoint of SUA increase, showed a 25% ABCG2 dysfunction to be equivalent to the effects of a 1.67 kg/m 2 increase in BMI, alcohol consumption of 154.2 g/week, an 18.6-year increase in age, and, in women, 42.7% due to menopause. In the tested female sample, the PAF for hyperuricemia due to ABCG2 dysfunction (32.8%) exceeded those for overweight/obesity (19.5%) and aging (28.7%). Menopausal status exhibited the highest PAF at 63.0%. In premenopausal individuals, the PAF for ABCG2 dysfunction was 45.8%, much higher than that after menopause (29.6%). Although premenopausal women generally had a lower prevalence of hyperuricemia than postmenopausal individuals, those with dysfunctional variants of ABCG2 tended to show a higher SUA increase and PAFs in premenopausal than in postmenopausal women. These results indicate that genetic testing might be helpful in preventing and treating hyperuricemia, particularly for those with higher SUA before menopause, in both individuals and in populations as a whole.
- Open Access
- 9 April 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (4) , e70535
Establishment of a Model to Predict the Prognosis of Endometrial Carcinoma Using Tumor‐Infiltrating Lymphocytes Evaluated With Artificial Intelligence: A Retrospective Analysis
Background: The objective of this study was to establish a new model for predicting the prognosis of endometrial carcinoma (EC) using tumor‐infiltrating lymphocytes (TILs) based on artificial intelligence (AI). Methods: Patients with EC who were treated between 1989 and 2022 were included in this study. For each patient, one hematoxylin and eosin‐stained slide containing the most invasive frontline of the tumor was selected and digitized. The area within a 500 μm width span, extending 250 μm toward the stroma and tumor from the manually annotated invasive frontline, was automatically annotated. The average number of lymphocytes per area (μm 2 ) in the annotated area was calculated using AI. Patients were classified into the High‐TIL and Low‐TIL groups, and survival analysis was conducted. Four mismatch repair (MMR)‐related proteins were evaluated using immunohistochemical staining. Results: A total of 659 patients were included: 346 (52.5%) in the High‐TIL group and 313 (47.5%) in the Low‐TIL group. MMR deficiency was observed more frequently in the High‐TIL group than in the Low‐TIL group ( p < 0.01). Progression‐free survival (PFS) and overall survival (OS) were better in the High‐TIL group than in the Low‐TIL group (both p < 0.01). Multivariate analysis revealed that TIL status was a prognostic factor for PFS (hazard ratio [HR] (95% confidence interval [CI]) 0.61 (0.43–0.87); p < 0.01) and OS (HR (95% CI) 0.54 (0.33–0.86); p = 0.01). Conclusion: TILs evaluated using AI could accurately and significantly predict the prognosis of EC. Further studies are needed to establish new methods for evaluating TILs in ECs.
- 9 April 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (4) , e70535
Open AccessEstablishment of a Model to Predict the Prognosis of Endometrial Carcinoma Using Tumor‐Infiltrating Lymphocytes Evaluated With Artificial Intelligence: A Retrospective Analysis
Background: The objective of this study was to establish a new model for predicting the prognosis of endometrial carcinoma (EC) using tumor‐infiltrating lymphocytes (TILs) based on artificial intelligence (AI). Methods: Patients with EC who were treated between 1989 and 2022 were included in this study. For each patient, one hematoxylin and eosin‐stained slide containing the most invasive frontline of the tumor was selected and digitized. The area within a 500 μm width span, extending 250 μm toward the stroma and tumor from the manually annotated invasive frontline, was automatically annotated. The average number of lymphocytes per area (μm 2 ) in the annotated area was calculated using AI. Patients were classified into the High‐TIL and Low‐TIL groups, and survival analysis was conducted. Four mismatch repair (MMR)‐related proteins were evaluated using immunohistochemical staining. Results: A total of 659 patients were included: 346 (52.5%) in the High‐TIL group and 313 (47.5%) in the Low‐TIL group. MMR deficiency was observed more frequently in the High‐TIL group than in the Low‐TIL group ( p < 0.01). Progression‐free survival (PFS) and overall survival (OS) were better in the High‐TIL group than in the Low‐TIL group (both p < 0.01). Multivariate analysis revealed that TIL status was a prognostic factor for PFS (hazard ratio [HR] (95% confidence interval [CI]) 0.61 (0.43–0.87); p < 0.01) and OS (HR (95% CI) 0.54 (0.33–0.86); p = 0.01). Conclusion: TILs evaluated using AI could accurately and significantly predict the prognosis of EC. Further studies are needed to establish new methods for evaluating TILs in ECs.
- Open Access
- 1 January 2026
- Published by Wiley in Obstetrics and Gynecology International
- Vol. 2026 (1)
Cesarean Section at 38 Gestational Weeks for Placenta Previa was Associated With Improved Neonatal Outcomes Without an Apparent Increase in Maternal Risks: A Historical Control Study
Background and Aims: The optimal timing of cesarean delivery in women with placenta previa (PP) remains controversial because earlier delivery may reduce maternal risks, whereas later delivery may improve neonatal outcomes. This study aimed to evaluate whether delaying planned cesarean section (CS) until 38 gestational weeks was associated with improved neonatal outcomes without increasing maternal risks in women with PP who remain clinically stable. Methods: This historical control study included women with singleton pregnancies complicated by PP who underwent CS at a single tertiary center between 2015 and 2024. Planned CS was scheduled at 38 +0 to 38 +6 gestational weeks between 2022 and 2024 and at 36 +0 to 37 +6 gestational weeks between 2015 and 2022. Women who underwent emergency CS or developed obstetric complications, including antepartum hemorrhage or threatened preterm labor, were excluded from the primary analysis. Women who underwent planned CS at the scheduled gestational weeks were assigned to Group A (38‐week group) and Group B (36–37‐week group). Maternal and neonatal outcomes were compared between the groups. Results: Of the 204 eligible women, 29 were included in Group A and 81 in Group B. Maternal outcomes, including blood loss, operation time, and rates of severe complications, were comparable between the groups. In contrast, neonatal outcomes were improved in Group A, with higher birthweight and lower rates of neonatal hospitalization and hypoglycemia. Most obstetric complications occurred before 36 gestational weeks in both periods. Conclusion: Delaying planned CS until 38 gestational weeks in clinically stable women with PP was associated with improved neonatal outcomes without an apparent increase in maternal risks or emergency CS. These findings support further investigation of the optimal timing of delivery in women with PP.
- 1 January 2026
- Published by Wiley in Obstetrics and Gynecology International
- Vol. 2026 (1)
Open AccessCesarean Section at 38 Gestational Weeks for Placenta Previa was Associated With Improved Neonatal Outcomes Without an Apparent Increase in Maternal Risks: A Historical Control Study
Background and Aims: The optimal timing of cesarean delivery in women with placenta previa (PP) remains controversial because earlier delivery may reduce maternal risks, whereas later delivery may improve neonatal outcomes. This study aimed to evaluate whether delaying planned cesarean section (CS) until 38 gestational weeks was associated with improved neonatal outcomes without increasing maternal risks in women with PP who remain clinically stable. Methods: This historical control study included women with singleton pregnancies complicated by PP who underwent CS at a single tertiary center between 2015 and 2024. Planned CS was scheduled at 38 +0 to 38 +6 gestational weeks between 2022 and 2024 and at 36 +0 to 37 +6 gestational weeks between 2015 and 2022. Women who underwent emergency CS or developed obstetric complications, including antepartum hemorrhage or threatened preterm labor, were excluded from the primary analysis. Women who underwent planned CS at the scheduled gestational weeks were assigned to Group A (38‐week group) and Group B (36–37‐week group). Maternal and neonatal outcomes were compared between the groups. Results: Of the 204 eligible women, 29 were included in Group A and 81 in Group B. Maternal outcomes, including blood loss, operation time, and rates of severe complications, were comparable between the groups. In contrast, neonatal outcomes were improved in Group A, with higher birthweight and lower rates of neonatal hospitalization and hypoglycemia. Most obstetric complications occurred before 36 gestational weeks in both periods. Conclusion: Delaying planned CS until 38 gestational weeks in clinically stable women with PP was associated with improved neonatal outcomes without an apparent increase in maternal risks or emergency CS. These findings support further investigation of the optimal timing of delivery in women with PP.
- Open Access
- 26 December 2025
- Published by Springer Nature in Human Cell
- Vol. 39 (1) , 22
Dysfunctional variants of ABCG2 create strong individual and population risks for progression of hyperuricemia: the potential for implementation of genome-personalized nursing
Gout, a common disease, develops after prolonged hyperuricemia with elevated serum uric acid (SUA) levels. Sex, overweight/obesity, heavy drinking, and aging all increase risk. Common dysfunctional variants (polymorphisms) in the ABCG2/BCRP gene are major genetic causes of gout/hyperuricemia. Early management would thus have potential benefits for public health. Several studies report the effectiveness of nurse-led care for gout management. We evaluate here the individual and population genetic effects of ABCG2 in 9244 Japanese study participants, in all of whom ABCG2 variants had a higher population-attributable fraction (PAF; approximately 30%) for progression of hyperuricemia than those for other typical environmental risk factors (overweight/obesity, heavy drinking, and aging). PAFs for aging in males and heavy drinking in females were not significant. All these factors also showed significant individual risk of increased SUA level, and ABCG2 variants had sufficient effect size to allow them to be converted into other environmental factors. To implement genome-personalized nursing, we then mapped onto the process a theoretical framework that is based on a psychological model from behavioral change theory. Because the present results for convertibility will improve the predictability of genetic effects, cognitive interventions by nurses based on individual variants could therefore encourage both inducements of behavioral change: efficacy expectations (self-efficacy) and outcome expectations. We conclude that the framework would function effectively based on cognitive interventions by nurses/paramedics. This theoretical framework has potential as a basis for implementing genome-personalized prevention, medicine and nursing of gout/hyperuricemia, and for optimizing nurse-led care.
- 26 December 2025
- Published by Springer Nature in Human Cell
- Vol. 39 (1) , 22
Open AccessDysfunctional variants of ABCG2 create strong individual and population risks for progression of hyperuricemia: the potential for implementation of genome-personalized nursing
Gout, a common disease, develops after prolonged hyperuricemia with elevated serum uric acid (SUA) levels. Sex, overweight/obesity, heavy drinking, and aging all increase risk. Common dysfunctional variants (polymorphisms) in the ABCG2/BCRP gene are major genetic causes of gout/hyperuricemia. Early management would thus have potential benefits for public health. Several studies report the effectiveness of nurse-led care for gout management. We evaluate here the individual and population genetic effects of ABCG2 in 9244 Japanese study participants, in all of whom ABCG2 variants had a higher population-attributable fraction (PAF; approximately 30%) for progression of hyperuricemia than those for other typical environmental risk factors (overweight/obesity, heavy drinking, and aging). PAFs for aging in males and heavy drinking in females were not significant. All these factors also showed significant individual risk of increased SUA level, and ABCG2 variants had sufficient effect size to allow them to be converted into other environmental factors. To implement genome-personalized nursing, we then mapped onto the process a theoretical framework that is based on a psychological model from behavioral change theory. Because the present results for convertibility will improve the predictability of genetic effects, cognitive interventions by nurses based on individual variants could therefore encourage both inducements of behavioral change: efficacy expectations (self-efficacy) and outcome expectations. We conclude that the framework would function effectively based on cognitive interventions by nurses/paramedics. This theoretical framework has potential as a basis for implementing genome-personalized prevention, medicine and nursing of gout/hyperuricemia, and for optimizing nurse-led care.